

Ebola Current Awareness Bulletin– May 2026



Figure 1 NHS Lanarkshire Logo

Contents

Ebola **Error! Bookmark not defined.**

End of Document 6

Ebola

1. Abdelrahman AHM, Mekhemer GAH, Sidhom PA, et al. [Drug Repurposing Investigation for Combating Ebola Virus Disease: Database Mining, Docking Calculations, Molecular Dynamics, and Density Functional Theory Study](#). *ChemistryOpen*. 2025;14(12):14. no pagination
2. Ait LN, Wissal L, Saad Z, et al. [QSAR-Guided and Fragment-Based Drug Design of Monoterpenoid Inhibitors Targeting Ebola Virus Glycoprotein](#). *Int J Mol Sci*. 2026;27(7):2987. no pagination
3. Bepouka B, Kafua M, Matangi B, et al. [Simultaneous outbreaks of Ebola, cholera, mpox, and measles in DR Congo in 2025](#). *Lancet*. 2025;406(10516):2214-2215.

4. Boer NA, Emperador DM, Eckerle I, et al. [Evaluating the impact of trade-offs in diagnostic test accuracy, time-to-isolation, and accessibility on outbreak response for the Ebola virus: a mathematical modeling study](#). *BMC Infect Dis*. 2025;25(1):1122. no pagination
5. Bryan ME, Nzanzu Vivalya BM, Geisbert TW, et al. [Ebola virus in Kasai revives 50-year-old questions on viral latency](#). *Lancet*. 2025;406(10513):1723. no pagination
6. Catherine O, Burch M, Dennis B. [Skin Deep: Uncovering the Early Events of Crimean–Congo Hemorrhagic Fever Virus at the Tick–Host–Virus Interface](#). *Viruses*. 2026;18(4):429. no pagination
7. Davies KA, Welch SR, Harcourt BH, et al. [Inactivation of Ebola, Nipah, and Lassa viruses in tissue using neutral buffered formalin, MagMAX lysis/binding solution, or TriPure isolation reagent](#). *Sci Rep*. 2026;16(1):3712. no pagination
8. Elliff J, Grady L, O'Donnell KL, et al. [Acute malaria dysregulates specialized lymph node macrophages to suppress vaccine-elicited protection against the Ebola virus](#). *mBio*. 2026;17(2):31. no pagination
9. Escudero-Pérez B, Lasala F, Luczkowiak J, et al. [Oral immunization with filovirus-like particles partially protects IFNAR–/– mice against lethal ebola virus challenge](#). *Sci Rep*. 2026;16(1):15022. no pagination
10. Eteng WO, Ilesanmi OS, Imo CU, et al. [Commemorating a decade of service: Reflections on Nigeria's deployment of 196 public health professionals to Liberia and Sierra Leone during the 2014–2015 Ebola crisis](#). *J Public Health Afr*. 2026;17(1):7. no pagination
11. Gani S, Ivanka S, Neli S, et al. [Stability of Sets for Ebola Virus Disease Models Through Impulsive Conformable Approach](#). *Mathematics*. 2026;14(7):1108. no pagination
12. Garcia-Fogeda I, Abrams S, Vanhee S, et al. [Within-host mathematical models to study antibody kinetics after the prophylactic Ebola vaccine in the Democratic Republic of the Congo](#). *Vaccine*. 2025;64:11. no pagination
13. Gonzalez A, Nikparvar B, Matson MJ, et al. [Links between infrastructure for human movement and early Ebola outbreak trajectories](#). *Sci Rep*. 2026;16(1):3920. no pagination
14. Goswami R, Piccolo AL, Miller R, et al. [Healthcare Worker Attitudes and Perceptions toward Ebola Vaccine, United States, 2024](#). *Emerg Infect Dis*. 2025;31(12):5. no pagination
15. Iampietro M, Periasamy S, Ilinykh PA, et al. [Distinct immune properties of the N- and C-termini of the immunosuppressive domain of Ebola virus glycoprotein](#). *mBio*. 2025;16(11):23. no pagination
16. Jeong-Hyun L, Jung S, Hwajung Y, Yoon-Seok C. [Standardized Diagnostic Assays for Omsk Hemorrhagic Fever Virus](#). *Pathogens*. 2025;14(11):1093. no pagination

17. Johnston SC, Ginnetti AT, Twenhafel NA, et al. [Efficacy evaluation of the S-adenosylhomocysteine hydrolase inhibitor MSD-914 in rhesus macaques \(*Macaca mulatta*\) challenged with Ebola virus by the intramuscular route](#). *PLoS One*. 2026;21(2):23. no pagination
18. Jonah E, Hanora VE, Sevcik K, et al. [Interferons Inhibit Ebola Virus Infection of Human Keratinocytes](#). *Viruses*. 2025;17(12):1577. no pagination
19. Kallay R, Muhoza P, Tchoualeu DD, et al. [Perceptions of factors influencing Ebola vaccine acceptance among community members, healthcare workers, and response personnel in Eastern Democratic Republic of the Congo](#). *PLoS One*. 2026;21(4):19. no pagination
20. Kämper L, Kuhl I, Vallbracht M, et al. [To be or not to be phosphorylated: understanding the role of Ebola virus nucleoprotein in the dynamic interplay with the transcriptional activator VP30 and the host phosphatase PP2A-B56](#). *Emerg Microbes Infect*. 2025;14(1):15. no pagination
21. Kennedy E, Findlay-Wilson S, Webster S, et al. [A hyperimmune ovine antibody-based therapeutic candidate against Crimean–Congo haemorrhagic fever virus targeted to the Gn and Gc glycoproteins: high antibody levels with neutralization activity but lack of protective efficacy in a mouse model](#). *Antib Ther*. 2026;9(2):179. no pagination
22. Kikwango EM, Akilimali PZ, Tran NT. [Impact of most promising Ebola therapies on survival: a secondary analysis during the tenth outbreak in the Democratic Republic of Congo](#). *Virol J*. 2025;22(1):144. no pagination
23. Kyle W, Garnett L, Bello A, Strong JE. [CRISPR-Based Detection of Viral Hemorrhagic Fevers at the Point of Care](#). *Viruses*. 2026;18(2):218. no pagination
24. Li H, Pickering BS. [Viral RNA persistence and long-term consequences following acute infection with Risk Group 4 zoonotic viruses](#). *Front Cell Infect Microbiol*. 2026;16:1809435. no pagination
25. Li Z, Dai J, Yang Z, et al. [A Rapid RT-RAA Assay for Visual Detection of Ebola Virus: Advancing Early Diagnosis in Resource-Limited Settings](#). *Pathogens*. 2025;14(12):1266. no pagination.
26. Lupascu D, Iacob AT, Apotrosoaei M, et al. [Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review](#). *Pharmaceutics*. 2026;18(4):426. no pagination
27. Lyons P, Winters M, Jalloh MF, et al. [Building confidence in crises – the roles of Sierra Leonean religious leaders’ during the 2014–2016 Ebola outbreak](#). *Glob Health Action*. 2025;18(1):12. no pagination
28. Ma X, Xu ZS, Fu Y, et al. [Soluble MFGE8 mediates cell entry of Crimean-Congo hemorrhagic fever virus](#). *mBio*. 2025;16(10):20. no pagination

29. Machuetum GL, Tchatchueng-Mbougua JB, Munyeku-Bazitama Y, et al. [Detection of Crimean-Congo hemorrhagic fever virus and Rift Valley fever virus antibodies in animal workers in Cameroon](#). *Front Vet Sci*. 2025;12:1646715. no pagination
30. Malathy R, Krishnan GS, Loganathan K. [A Caputo fractional-order SEIHRD model for Ebola: theoretical analysis, sensitivity, bifurcation, and numerical simulations](#). *Sci Rep*. 2026;16(1):13661. no pagination
31. Mamede I, Luschër-Dias T, Isabelle FM, et al. [Long non-coding RNAs in response to Ebola virus vaccine-induced immunity](#). *Front Immunol*. 2026;16:1695514. no pagination
32. Mani V, Chu WT, Yang H, et al. [Reactive oxygen species-related oxidative changes are associated with splenic lymphocyte depletion in Ebola virus infection](#). *NPJ Imaging*. 2025;3(1):16. no pagination
33. Mehrotra P, Mathew T, Trulik KG, et al. [Sports fever! Getting the ball rolling to prevent infections at the World Cup™ and beyond](#). *Antimicrob Steward Healthc Epidemiol*. 2026;6(1):8. no pagination
34. Mihalakakos EA, Ssempijja V, Ribeiro RM, et al. [Longitudinal seroprevalence of Crimean-Congo hemorrhagic fever virus in Southern Uganda](#). *Emerg Microbes Infect*. 2025;14(1):12. no pagination
35. Morais GCF, de Souza Sena CP, Silva GVR, et al. [Comprehensive evaluation of potential EBOV inhibitors using advanced molecular modeling techniques: implications for anti-Ebola therapeutics and rational drug design](#). *Future J Pharm Sci*. 2025;11(1):145. no pagination
36. Moreno-Contreras J, Peñaflor-Tellez Y, Ricardo R. [The Role of Posttranslational Modifications During Ebola Virus Infection](#). *Viruses*. 2025;17(12):1640. no pagination
37. Mwamba D, Mboussou F, Akilimali P, et al. [New Ebola virus disease outbreak in the Democratic Republic of the Congo: early response guidance](#). *Lancet*. 2025;406(10512):1557-1558.
38. Ngatu NR, Sakiko K, Christian W, et al. [Occupational Infection Prevention Among Nurses and Laboratory Technicians Amidst Multiple Health Emergencies in Outbreak-Prone Country, D.R. Congo](#). *Trop Med Infect Dis*. 2026;11(1):14. no pagination
39. Ogunniyi TJ, Fatokun BS, Olorunfemi OA, et al. [Health system resilience in Nigeria after Ebola and COVID-19: impacts, improvements, and strategic directions](#). *Discov Public Health*. 2025;22(1):582. no pagination
40. Paasi G, Okware S, Olupot-Olupot P. [The Impact of Diagnostic Delays and Timeliness of Response on Ebola Disease outbreak-level case-fatality Ratios in Uganda \(2000–2023\): a Rapid Systematic Review and meta-analysis](#). *J Epidemiol Glob Health*. 2025;15(1):130. no pagination

41. Phelps AL, Lin E, Findlay JS, et al. [Long-Term Efficacy of Disinfectants Against Ebola Virus and Nipah Virus for Use in Containment Level 4 Laboratories](#). *Viruses*. 2026;18(3):314. no pagination
42. Shamamba SM, Jean-Christophe SM, Horton AC, Kasumba DM. [Venturing into host-pathogen interaction in Crimean-Congo hemorrhagic fever to highlight terra incognita](#). *Front Immunol*. 2026;17:1735683. no pagination
43. Stromberg ZR, Silva EE, Johnston SC, et al. [An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models](#). *Front Immunol*. 2026;16:1682418. no pagination
44. Takamatsu Y, Dolnik O, Hirabayashi A, et al. [Molecular insights into nucleocapsid assembly and transport in Marburg and Ebola viruses](#). *mBio*. 2025;16(11):25. no pagination
45. [The current Ebola outbreak is a public health emergency of international concern](#). *Nat Commun*. 2026;17(1):4603. no pagination
46. Tshimbombu TN. [A diagnostic void in the Congo Basin: proposing a zoonotic orthopoxvirus as the cause of a hemorrhagic fever outbreak and a call for equitable health security](#). *Infect Dis Poverty*. 2025;14(1):118. no pagination
47. Valayer S, Alexandre M, Prague M, et al. [Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial](#). *Emerg Microbes Infect*. 2025;14(1):12. no pagination
48. Van Geertruyden J, Larivière Y, Zola Matuvanga T, et al. [Ebola and health-care providers: the case for preventive vaccination](#). *Lancet*. 2026;407(10525):219-220.
49. Wafa H, Balakumar C, Sankar M, Pandi B. [Computational Molecular Docking and Molecular Dynamics Simulations of Potential Inhibitors from Cistus incanus \(Cistaceae\) Against Ebola Virus](#). *Biophysica*. 2026;6(2):29. no pagination
50. Wang M, Zhang X, Li W, et al. [A highly potent nanobody-based bispecific therapeutic provides broad-spectrum protection against ebolavirus](#). *Nat Commun*. 2026;17(1):4040. no pagination
51. Zarro M, Bashlakova K, Brunone S, et al. [Efficacy and safety of Ebola vaccines in children: a systematic review and meta-analysis](#). *Eur J Public Health*. 2025;35:3. no pagination
52. Zhang X, Liu X, Zhou J, et al. [Computational Design of Broad-Spectrum Ebola Antibodies through Framework and Complementarity-Determining Region Synergistic Optimization](#). *Research*. 2026;9:1211. no pagination

53. Zhao G, Korva M, Muñoz-Fontela C, et al. [Delayed type I interferon response and the subsequent out-of-sequence cytokine signal inhibit T cell induction in non-surviving Ebola virus-infected patients](#). *Front Immunol*. 2026;17:1806697. no pagination

End of Document